2 recruiting, 2 unknown. 4 Phase 2, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 4 | Recruiting 2, Unknown 2 |
| Phase 1 | 1 | Recruiting 1 |
Follow Chronic Myeloid Leukemia - Accelerated Phase: new trials by email Literature Review of Chronic Myeloid Leukemia - Accelerated Phase trials Research Report on Chronic Myeloid Leukemia - Accelerated Phase
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Intensity Modulated Total Marrow Irradiation in Fully Human Leukocyte Antigen (HLA)-Matched and Partially-HLA Mismatched Allogeneic Transplantation Patients With High-Risk Acute Myeloid Leukemia (AML), Chronic Myeloid Leukemia (CML), and Myelodysplastic Syndrome (MDS) Intensity modulated total marrow irradiation, Cyclophosphamide (CTX), Fludarabine (Fludara) - Acute Myeloid Leukemia, Relapsed, Adult, Acute Myeloid Leukemia Refractory | Phase 2 | Recruiting | University of Illinois at Chicago | 38 | 2025-02-04 | 2026-06-26 |
| Phase I/II Trial: Engineered Donor Graft (Orca Q) for Pediatric Hematopoietic Cell Transplant (HCT) Orca-Q - Acute Myeloid Leukemia, Acute Lymphoid Leukemia | Phase 1 / Phase 2 | Recruiting | University of Florida | 40 | 2022-08-16 | 2026-09-01 |
| Decitabine and HQP1351-based Chemotherapy Regimen for the Treatment Advanced CML based decitabine and olverembatinib（HQP1351)chemotherapy - Chronic Myeloid Leukemia in Myeloid Blast Crisis, Chronic Myeloid Leukaemia Transformation | Phase 2 | Unknown | Nanfang Hospital, Southern Medical University | 40 | 2021-12-01 | 2022-12-08 |
| A Pivotal Study of HQP1351 in Patients of Chronic Myeloid Leukemia in Accelerated Phase With T315I Mutation HQP1351 - Chronic Myeloid Leukemia - Accelerated Phase | Phase 2 | Unknown | Ascentage Pharma Group Inc. | 23 | 2019-04-08 | 2023-04-03 |
Leukemia, Myeloid, Accelerated Phase (4) · Leukemia, Myeloid, Acute (2) · Disease (1) · Hematologic Neoplasms (1) · Leukemia, Biphenotypic, Acute (1) · Myelodysplastic Syndromes (1) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (1) · Recurrence (1)
Bone Marrow Diseases (4) · Chronic Disease (4) · Disease Attributes (4) · Hematologic Diseases (4) · Hemic and Lymphatic Diseases (4) · Leukemia (4) · Leukemia, Myelogenous, Chronic, BCR-ABL Positive (4) · Leukemia, Myeloid (4) · Myeloproliferative Disorders (4) · Neoplasms (4) · Neoplasms by Histologic Type (4) · Pathologic Processes (4) · Pathological Conditions, Signs and Symptoms (4) · Immune System Diseases (1) · Immunoproliferative Disorders (1)
Busulfan (1) · Cyclophosphamide (1) · fludarabine (1) · fludarabine phosphate (1) · olverembatinib (1)
Ascentage Pharma Group Inc. (1) · Nanfang Hospital, Southern Medical University (1) · University of Florida (1) · University of Illinois at Chicago (1)
China (2) · United States (2)
Jordan Milner, MD (1) · Matias Sanchez, MD (1) · Qian Jiang, Professor (1) · Xiaojun Huang, Professor (1)